Athersys CEO elected chair of regenerative medicine trade group
Athersys Inc. CEO Gil Van Bokkelen has been elected chairman of the The Alliance for Regenerative Medicine.
Athersys Inc. CEO Gil Van Bokkelen has been elected chairman of the The Alliance for Regenerative Medicine.
An FDA panel's decision to reject the obesity drug lorcaserin shouldn't affect Athersys Inc.'s (NASDAQ: ATHX) development of a similar drug, the Cleveland-based company's chief executive said.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biopharmaceutical company Athersys Inc. is looking for commercial partners to help it develop and test its stem cell and drug therapies aimed at treating a variety of health problems. The company reported a narrowed loss and lower revenues in the second quarter from a year ago.